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ABSTRACT 
 
Background Cutaneous malignant melanoma (CMM) is one of the most rapidly increasing cancers in 
Sweden, as in many other western countries. In clinical practice, the histopathological evaluation has 
remained the basis for staging the CMMs and, thus, providing important information on prognosis and on 
therapeutic recommendations. Interobserver variation regarding the histopathological evaluation is known to 
exist. However, few studies have investigated how clinical, biological and social mechanisms interact and 
influence the prognosis in CMM. For patients with advanced disease progress of the treatment options has 
been achieved for tumours carrying BRAF
V600 
mutations by the development of specific small-molecule 
BRAF inhibitors. The development of these targeted therapies thus mandates determination of BRAF 
mutation status. This thesis aims to describe the interobserver variability in evaluating histopathological 
prognostic factors, to assess the association between education as well as cohabitation status and prognosis 
in patients with a primary CMM, and also to analyze the patterns of BRAF
V600E
 protein expression in 
primary and metastatic CMMs. 
 
Methods In Paper I, a total of 234 cases of invasive CMMs from the Stockholm–Gotland Healthcare Region 
in Sweden were included in the study. In Papers II and III, 27,235 patients diagnosed with a primary 
invasive CMM between 1990 and 2007 were identified from the Swedish Melanoma Register. Data were 
linked to nationwide, population based, health and census registers with a follow-up through 2010. In Paper 
IV, a total of 200 CMMs were stained by immunohistochemistry (IHC) using a BRAF
V600E
 specific 
monoclonal antibody (VE1).  
 
Results Overall, interobserver variability between a general pathologist and an expert review was 79% in 
Paper I. The best agreement was found for tumour thickness, but 15.5% of the tumours were re-classified 
after review in a sub-set of thin (≤ 1 mm) CMMs 15.5% were re-classified. 
In Paper II, we found significantly elevated odds ratios (OR) of higher disease stage at diagnosis among 
lower education groups after adjustments for other prognostic factors (OR stage II vs. I = 1.6; 95% 
confidence interval (CI) = 1.5-1.7. OR stage III–IV vs. I = 2.3; 95% CI = 1.8-2.9). The risk of dying of 
CMM, was significantly increased in patients with low education after the final adjustments for all clinical 
and histopathological prognostic factors (hazard ratio (HR) low vs. high = 1.13; 95% CI=1.01-1.27; p = 
0.04). 
In Paper III, after adjustments for established prognosticators and education, the ORs of higher clinical stage 
at diagnosis were significantly increased among men living alone vs. men living with a partner (OR stage II 
vs. stage I = 1.42; 95% CI = 1.29-1.57. OR stage III-IV vs. stage I = 1.43; 95% CI = 1.14-1.79). The ORs for 
higher stage among women living alone were also increased (OR stage II vs. stage I = 1.15; 95% CI = 1.04-
1.28. OR stage III-IV vs. stage I = 1.04; 95% CI = 0.79-1.37). After adjustments for all potential and 
established prognostic factors, HR for CMM death for men living alone vs. living with a partner was 1.33 
(95% CI = 1.19-1.49; p<0.0001), indicating a residual adverse effect on survival not accounted for by these 
parameters. 
In Paper IV, the VE1 IHC staining intensity varied between primary CMMs and matched metastases in 47% 
of the cases, as well as between separate metastases. We found a sensitivity of the VE1 antibody of 97% and 
a specificity of 80% for detection of BRAF
V600E
 mutations. A comparable sensitivity was obtained for 
primary CMMs and metastases when analyzed separately. However, the specificity was lower among 
primary CMMs (71%) compared to metastases (93%). 
 
Conclusions Our results imply that the recommendation of surgical excision margins and/or sentinel node 
biopsy changed in subgroups of thin CMMs after a CMM-expert pathology review. Moreover, the results 
emphasize the need for improved early detection strategies directed towards specific patient groups to 
improve the CMM-specific survival. IHC using the VE1 antibody should be used in combination with 
genomic testing in primary CMMs specifically in cases with weak/moderate staining to accurately predict 
BRAF
V600E
 status, whereas in metastases with strong VE1 staining no further mutation testing seems to be 
required. 
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